Geopolitics Alpha

L&G upbeat on earnings; AstraZeneca wins approvals

Published . Updated .

Market Call

Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.

Get these market calls by email

The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.

Free. We only use your email to send the digest, never sell or share it, and every email has a one-click unsubscribe link. See our privacy policy.

GEOPOLITICS ALPHAL&G upbeat on earnings;AstraZeneca wins approvalsAZNGEOPOLITICS ALPHA

This report does not map to a usual set of affected companies.

Directly affected

  • AZN Astrazeneca+13.7% 30d

    Named in this report.

Indirectly affected

  • XLV Health Care Select Sector SPDR

    Health Care Select Sector SPDR holds the health sector that AstraZeneca belongs to, so it often moves with news about it.

  • NVS Novartis AG-4.2% 7d

    Novartis AG is a peer of AstraZeneca in pharmaceutical preparations; rivals often move on the same news.

  • NVO Novo Nordisk A/S-0.1% 30d

    Novo Nordisk A/S is a peer of AstraZeneca in pharmaceutical preparations; rivals often move on the same news.

  • GSK Gsk+0.7% 5d

    Gsk is a peer of AstraZeneca in pharmaceutical preparations; rivals often move on the same news.

  • SNY Sanofi

    Sanofi is a peer of AstraZeneca in pharmaceutical preparations; rivals often move on the same news.

  • ROIV Roivant Sciences+14.5% 18d

    Roivant Sciences is a peer of AstraZeneca in pharmaceutical preparations; rivals often move on the same news.

Price reaction, T-5 to T+3

TickerT-5T-3T-1T0T+1T+2T+3
AZN+2.66%+0.56%baseafter closeafter closeafter closeafter close
XLV-0.28%+0.04%baseafter closeafter closeafter closeafter close
NVS+1.94%-0.11%baseafter closeafter closeafter closeafter close
NVO-0.56%-1.26%baseafter closeafter closeafter closeafter close
GSK+2.17%+0.30%baseafter closeafter closeafter closeafter close
SNY-0.53%+0.12%baseafter closeafter closeafter closeafter close
ROIV+2.90%+5.90%baseafter closeafter closeafter closeafter close

Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.

L&G upbeat on earnings; AstraZeneca wins approvals marketscreener.com

Source: marketscreener.com

This story

CompanyWhenMoveStatus
AZNthree days earlier+0.56%final price
AZNfive days earlier+2.66%final price
GSKthree days earlier+0.30%final price
GSKfive days earlier+2.17%final price
NVOthree days earlier-1.26%final price
NVOfive days earlier-0.56%final price
NVSthree days earlier-0.11%final price
NVSfive days earlier+1.94%final price
ROIVthree days earlier+5.90%final price
ROIVfive days earlier+2.90%final price
SNYthree days earlier+0.12%final price
SNYfive days earlier-0.53%final price
XLVthree days earlier+0.04%final price
XLVfive days earlier-0.28%final price

Congressional trades in the stocks in this story

Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).

How solid “L&G upbeat on earnings; AstraZeneca wins approvals” looks

12 out of 100

“L&G upbeat on earnings; AstraZeneca wins approvals” scores 12 out of 100. The score uses 1 sources.